Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Cancer stem cells depend on amino acid metabolism, and it's proving to be their Achilles' heel

Cancer stem cells depend on amino acid metabolism, and it's proving to be their Achilles' heel

Researchers develop first chemical inhibitors for treatment of acute myeloid leukemia

Researchers develop first chemical inhibitors for treatment of acute myeloid leukemia

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Two-cells-in-one combo therapy shows promise in strengthening leukemia treatment

Two-cells-in-one combo therapy shows promise in strengthening leukemia treatment

Scientists identify new target for battling deadly form of leukemia

Scientists identify new target for battling deadly form of leukemia

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Researchers caution that expediting HLH treatment may miss underlying cancers

Researchers caution that expediting HLH treatment may miss underlying cancers

Researchers design new combination therapy for reducing NSCLC cell growth

Researchers design new combination therapy for reducing NSCLC cell growth

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

Research shows possibility to postpone cumbersome treatment for low-risk MDS patients

Drug combination targets pre-leukemia stem cells

Drug combination targets pre-leukemia stem cells

Scientists develop first DNA-based test for predicting risk of leukemia relapse

Scientists develop first DNA-based test for predicting risk of leukemia relapse

Researchers identify new cancerous cells responsible for acute myeloid leukemia relapse

Researchers identify new cancerous cells responsible for acute myeloid leukemia relapse

HU researchers develop new biological drug that may cure acute myeloid leukemia

HU researchers develop new biological drug that may cure acute myeloid leukemia

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Aravive Biologics gains Fast Track Designation for AVB-S6-500 from U.S. FDA

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials

Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials